The 35th Annual Congress of the European Association of Nuclear Medicine

Posted by Lizeth ⎜Aug 30, 2022 ⎜ Calendar Industry

isoSolutions will be attending the EANM Annual Meeting to be held, on October 15-19, 2022, in Barcelona, Spain. Arun Singh, the CEO, hopes to see you there. If you would like to arrange a time and place to meet him, please contact :

asingh@isosolutions.com

UPPI Annual In-Person Meeting

Posted by Lizeth ⎜Aug 30, 2022 ⎜ Calendar Industry

isoSolutions will be attending the United Pharmacy Partners (UPPI) Annual Meeting on September 14-15 in Charlotte, NC.  We are excited to be a   part of the event where we will be joined by our partner Elysia-raytest to highlight the Full QC Solution for Radiopharmacy in our presentation on Thursday, September 15th.  Neil Shirley, Sales Manager for USA and Canada, hopes to see you there.  If you would like to arrange a meeting with Neil during the event, please contact him at: nshirley@isosolutions.com

(more…)

SNMMI Annual Meeting 2022

Posted by Lizeth ⎜Apr 29, 2022 ⎜ Calendar Industry

isoSolutions is pleased to announce that we will be participating in the SNMMI Annual Meeting, the world’s largest event focused exclusively on meeting the educational and networking needs of the nuclear medicine and molecular imaging community. So please drop by at Booth # 1641 to say hello, and let’s chat!

We may be contacted at pacton@isosolutions.com and we would be happy to arrange a meeting to discuss your requirements.

Welcome to isoSolutions John Odom

Posted by Lizeth ⎜Mar 2, 2022 ⎜ Company Industry

Prior to joining isoSolutions, John worked as a Business Development Manager, Sales Engineer, and Technical Analyst of Network Operations for a variety of medical, energy and oil & gas organizations. His international experience in both North America and Europe includes selling advanced technology solutions, developing business development strategies and managing multi-million-dollar projects.

His educational background includes both the School of Engineering and Applied Science at Southern Methodist University and a variety of current technology / networking certificates. In his new role with isoSolutions John’s technical knowledge and sales skills, plus his ability to connect with people, will support isoSolutions’ business growth and the Teams’ skill in customer relations.

Chinese New Year 2022

Posted by Lizeth ⎜Feb 3, 2022 ⎜ Calendar Company

Tuesday, February 1st, 2022, and celebrations culminate with the Lantern Festival on February 15th, 2022.

Wishing you a prosperous and successful 2022. Happy Chinese New Year from Team isoSolutions!

CANM Annual Scientific Conference 2022

Posted by Lizeth ⎜Feb 3, 2022 ⎜ Calendar Company

The Canadian Association of Nuclear Medicine (CANM) has announced new dates for their 2022 Annual conference. It will now be held Sept 28-Oct 02, 2022 in Montreal, Quebec. Marvin Calderon or Patricia Acton, Sales Leaders, will be pleased to meet you there. They can be reached at:

Marvin Calderon: mcalderon@isosolutions.com

Patricia Acton: pacton@isosolutions.com

Additional information about CANM: https://www.canm-acmn.ca/

SNMMI 2022 Annual Meeting June 11-14, 2022 in Vancouver.

Posted by Lizeth ⎜Feb 3, 2022 ⎜ Calendar Company Industry

The SNMMI Annual Meeting is the world’s largest event focused exclusively on meeting the educational and networking needs of the nuclear medicine and molecular imaging community. Over 3,600 professional attendees are expected to participate in this meeting.

https://am.snmmi.org/iMIS/SNMMI-AM


We are happy that this year Vancouver will be the host city. Do not hesitate to get in touch with us any of our Sales representatives will be happy to assist you.

Happy Holidays

Posted by Lizeth ⎜Dec 23, 2021 ⎜ Company Industry

Welcome to isoSolutions Roger Lafortune

Posted by Lizeth ⎜Sep 29, 2021 ⎜ Company Industry

Roger will contribute to providing service for instruments and support our business growth efforts of Elysia-Raytest portfolio.  Prior to joining isoSolutions, Roger Lafortune worked as a Field Service Engineer for more than 10 years in the Healthcare system.

(more…)

SNMMI 2022 Annual Meeting

Posted by Lizeth ⎜Sep 13, 2021 ⎜ Calendar Industry

SNMMI 2022 Annual Meeting June 11-14, 2022 in Vancouver, BC, Canada. The SNMMI Annual Meeting is the world’s largest event focused exclusively on meeting the educational and networking needs of the nuclear medicine and molecular imaging community. Over 3,600 professional attendees are expected to participate in this meeting. isoSolutions will be excited to see you in person!  

We look forward to seeing you in Vancouver, B.C.

Q BioMed Signs Distribution Agreement with isoSolutions for the Sales of Strontium89 in Canada

Posted by Lizeth ⎜Aug 10, 2021 ⎜ Company Industry Products

Treatment with Strontium89 is available immediately in Canada via Named Patient Program

NEW YORK, Aug. 10, 2021 /PRNewswire/ — Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has recently entered into an exclusive distribution agreement with isoSolutions Marketing & Management Inc., a well-known distributor in Canada providing services and solutions to the nuclear medicine, radioisotope research, pharmaceutical, and medical device industries.  Under the terms of the agreement, isoSolutions has received exclusive rights to distribute Strontium89 in Canada.

Read More

CANM CONFERENCE

Posted by Lizeth ⎜Jul 19, 2021 ⎜ Calendar Industry

isoSolutions is glad to announce the next Virtual meeting for CANM will be on November 6th, 2021.  One-day conference.

Go to Website

PSMA-11-PET/CT versus choline-PET/CT to guide stereotactic ablative radiotherapy for androgen deprivation therapy deferral in patients with oligometastatic prostate cancer

Posted by Marvin Calderon ⎜Jul 8, 2021 ⎜ Industry

ABSTRACT

Background: In patients with oligometastatic recurrent prostate cancer, standard treatment is androgen deprivation therapy (ADT). However, ADT has many potential side effects that may result in impaired quality of life. Early identification to select patients suitable for stereotactic ablative radiotherapy (SABR) is of utmost importance to prevent or delay start of ADT and its side effects.

Because Prostate-Specific Membrane Antigen-11- Positron Emission Tomography (PSMA-11-PET) has a higher sensitivity than choline-PET, we hypothesise that PSMA-11-PET based SABR results in longer response duration and subsequent longer delay in starting ADT than choline-PET.

METHODS

Patients with oligometastatic (≤4 metastases) recurrent prostate cancer (with no local recurrence) based on PSMA-11-PET or choline-PET treated with SABR from January 2012 until December 2017 were included. Primary endpoint was ADT-free survival. Secondary endpoints were Prostate Specific Antigen (PSA) response after SABR and time to PSA rise after SABR.
Results: Fifty patients (n = 40 PSMA-11-PET and n = 10 choline-PET) with in total 72 lesions were included. Median follow-up was 24.3 months. PSMA-11-PET enabled eligibility of patients with lower PSA levels than choline-PET (median 1.8 versus 4.2 ng/mL, p = 0.03). The PSMA-11-PET group had a significant longer PSA response duration (median 34.0 months (95% confidence interval (CI), 16.0–52.0) versus 14.7 months (95% CI 4.7–24.7), p = 0.004) with a subsequent longer ADT-free survival (median 32.7 months (95% CI, 20.8–44.5) versus 14.9 months (95% CI, 5.7–24.1), p = 0.01).

CONCLUSION

With PSMA-11-PET we are able to select patients with oligometastatic recurrent prostate cancer suitable for SABR in an earlier disease stage at lower PSA levels. PSMA-11-PET guided SABR resulted in a significant longer response duration and ADT-free survival compared with choline-PET and can therefore prevent or delay ADT related side effects.

Read the full article

isoSolutions supports Lifetime Giving to Langara College Foundation

Posted by Lizeth ⎜Mar 10, 2021 ⎜ Company

isoSolutions Marketing & Management Inc. has been recognized for sponsoring over $5000 to the Lifetime Giving program of the Langara College Foundation.

David Drummond, Founder and President of isoSolutions, acknowledged the company’s commitment “isoSolutions values its association with the Langara College Foundation and will continue to support initiatives aimed at enabling success of students. We stay committed to doing our bit to nurture our community ties.”

Langara College Foundation is a community of donors and volunteers who are committed to expanding educational opportunities for students by supporting scholarship and bursaries, expanding delivery of student services and campus facilities, and funding beyond the classroom experiences. Additional information can be found at (https://langara.ca/foundation/)

THE CANM IS MOVING

Posted by Lizeth ⎜Mar 9, 2021 ⎜ Industry

The Canadian Association of Nuclear Medicine (CANM) Executive Director, Hélène Samson, retired on March 1, 2021. The CANM will be under the management of NAD Marketing Inc. with Nicolas Rondeau Lapierre the General Manager. Effective immediately the CANM will have a new office location and address, however the email and website addresses remain the same.
186, Val-Chenaie
Rosemère Québec, Canada J7A 4B6
(+1) 514-963-3269
Email:  canm@canm-acmn.ca
Website:  www.canm-acmn.ca

European Association of Nuclear Medicine

Posted by Lizeth ⎜Feb 17, 2021 ⎜ Calendar Industry

The 34th Annual Congress on October 20 – 23, 2021

The EANM’21 Congress and its Pre-Congress Symposia will be virtual.
The times stated refer to the timezone CEST (Central European Summer Time).  

Pre-Congress Symposia: October 4-6 & October 11-13, 2021

Main Congress: October 20 – 23, 2021

Go to website

Chinese New Year 2021

Posted by Lizeth ⎜Feb 10, 2021 ⎜ Calendar

February 12th, 2021, and celebrations culminate with the Lantern Festival on February 26th, 2021. Chinese New Year marks the transition between zodiac signs 2021 is the year of the Ox. Like isoSolutions, Oxen are known for strength, dependability, and patience. Happy Chinese New Year from Team isoSolutions! Wishing you a prosperous 2021!



SNMMI 2021 Annual Meeting

Posted by Patricia Acton ⎜Dec 1, 2020 ⎜ Calendar

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has announced its 2021 Annual Meeting, June 12 – 15, Washington, D.C. Recognizing that travel may not be possible, SNMMI is currently planning to offer a hybrid approach for the 2021 meeting. Both an in-person and virtual option will be provided, with the understanding that if conditions warrant, the meeting may transition to a 100% virtual event. As details are available they will be posted on (https://am.snmmi.org/iMIS/SNMMI-AM) . isoSolutions looks forward to its involvement in this upcoming Annual Meeting and will continue to work with SNMMI as exhibit options are developed.

CANM 2021 Annual Meeting

Posted by Patricia Acton ⎜Dec 1, 2020 ⎜ Calendar

CANM 2021 Annual Meeting – New dates!

The Board of the CANM and the Scientific Committee are happy to inform you that the CANM 2021 Annual Conference will take place at the Marriott Harbourfront Hotel in Halifax, September 30-October 2.

It has been moved from April to the Fall in order to have greater chances to host a live conference in 2021. Of course, should restrictions from Covid-19 still apply, the Association will revert to virtual sessions.

Please click here to view revised information regarding the 2021 conference: call for abstracts, emeritus award, hotel information, exhibitors’ information. Please consult the CANM Website regularly at www.canm-acmn.ca for updates.

isoSolutions Announces New Managing Director and Strategic Consultant

Posted by David T. Drummond ⎜Oct 2, 2020 ⎜ Company

isoSolutions Marketing and Management Inc. announces that Mr. David Drummond, Founder, and Managing Director, has decided to retire from the routine affairs of the company. He will continue to participate in the company as Strategic Consultant and President. The company is pleased to announce that Mr. Arun Kumar Singh, MSc MBA CSSMBB MCPM PMP, has replaced Mr. Drummond as Managing Director of isoSolutions. The owner of isoSolutions, Mr. Mark McCooey, stated: “isoSolutions remains committed to all of the business values instilled by David over the years of exemplary service. I am pleased Arun has joined isoSolutions and am confident that he will lead the company into an exciting future.”

Building a resilient Canadian Isotope supply chain critical for patients around the world

Posted by Marvin Calderon ⎜Jun 3, 2020 ⎜ Industry

New study to explore ways to strengthen delivery of life-saving medical isotopes

TORONTO – June 3, 2020) – The Nuclear Innovation Institute (NII) and Canadian Nuclear Isotope Council (CNIC) have partnered in an innovative study to identify challenges and evaluate potential technology, logistical, regulatory and policy solutions in Canada’s medical isotope supply chain.

Canada is a Leader in the production and Global supply of Isotopes. During the COVID-19 Pandemic, this has been never been more evident supplying critical Isotopes for medical equipment sterilization and the diagnosis and treatment of cancer.

(more…)

isoSolutions Marketing & Management Inc. and CNIC partner to promote nuclear medicine applications

Posted by Patricia Acton ⎜Feb 11, 2020 ⎜ Company

TORONTO – February 11, 2020 isoSolutions Marketing & Management Inc. (isoSolutions), an innovative one stop shop when it comes to nuclear medicine products has joined a growing list of organizations as members of the Canadian Nuclear Isotope Council (CNIC) an independent body made up of representatives from the Canadian health sector, nuclear industry and leading research groups, convened to promote Canada’s role in the production of the world’s supply of radioisotopes.

(more…)

Targeted Radionuclide Therapy

Posted by Marvin Calderon ⎜Feb 7, 2020 ⎜ Industry

Abstract :

Targeted radiotherapy is an evolving and promising modality of cancer treatment. The killing of cancer cells is achieved with the use of biological vectors and appropriate radionuclides. Among the many advantages of this approach are its selectiveness in delivering the radiation to the target, relatively less severe and infrequent side effects, and the possibility of assessing the uptake by the tumor prior to the therapy. Several different radiopharmaceuticals are currently being used by various administration routes and targeting mechanisms. This article aims to briefly review the current status of targeted radiotherapy as well as to outline the advantages and disadvantages of radionuclides used for this purpose.

(more…)

Two world leading research reactors join forces to create dual supply of medical isotope iodine-125

Posted by David T. Drummond ⎜Oct 14, 2019 ⎜ Industry

BARCELONA, Spain, 13th October 2019 – McMaster University’s Nuclear Reactor (CAN) and NRG (NL) announced today a unique collaboration between the Netherlands and Canada in the field of nuclear medicine.

Working together, these two globally renowned research reactors will provide the world with the highest quality radioiodine (I-125), used for the treatment of prostate and other various types of cancers, at the highest level of reliability.

The importance of readily available medical isotopes

Read the full article

Tags:

CSNMMI 2019 Meeting

Posted by Hans Peng ⎜Aug 19, 2019 ⎜ Calendar

The 13th National Conference of Nuclear Medicine and 2019 Annual meeting of Chinese Nuclear Medicine will take place in Kunming, Yunnan from 2019 September 19-22.

isoSolutions Marketing and Management’s Sales and Marketing Representative, China, Eric Huang (黄维超) will be attending the conference. If you would like to arrange a time to meet with Eric, please contact him at ehuang@isosolutions.com or +86-186 21264608

isoSolutions Welcomes Visitor from Uganda Charity

Posted by David T. Drummond ⎜Jul 17, 2019 ⎜ Company

isoSolutions was very pleased to welcome to its Vancouver office a visitor from the Abetavu children’s home in Uganda. Abetavu is a charity that isoSolutions has supported for several years. Our visitor from Abetavu – Ms. Tinah Praise – entered the Abetavu home in Uganda when she was 9 year old. She is now entering her second year of college in Kabale, Uganda.

Abetavu is an organization that started as an orphanage, founded by a Vancouver woman, Carli Travers, and her Ugandan husband Robert, nearly ten years ago. It is now so much more than an orphanage. Abetavu provides a safe haven to children that need support, and it provides essential services to the local community, in terms of counseling, education, sports, and many other services. Tinah is so grateful for having a chance at an education, something none of her other ten siblings were able to have. (more…)

Tags:

11th International Symposium on Targeted-Alpha-Therapy, 2019

Posted by David T. Drummond ⎜Jun 9, 2019 ⎜ Calendar

11th International Symposium on Targeted-Alpha-Therapy, April 1-5, 2019 in Ottawa, Ontario, Canada. isoSolutions is pleased to inform you that we will attend the 11th International Symposium on Targeted-Alpha-Therapy (TAT11). You can find us at booth 28 the Exhibit Hall at the Fairmont Chateau Laurier.

Neil Shirley, Sales Manager, United States and Canada, hopes to see you there. If you would like to arrange a time to meet with Neil, please contact him at nshirley@isosolutions.com

Hope to see you in Ottawa, Ontario.

Society of Nuclear Medicine and Molecular Imaging Annual Meeting 2019

Posted by David T. Drummond ⎜Jun 8, 2019 ⎜ Calendar

SNMMI 2019 Annual Meeting, June 22-25, 2019 in Anaheim, California.
isoSolutions is pleased to inform you that we will attend the Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). (more…)

Tags:

Sales and Marketing Manager, Asia Appointed

Posted by David T. Drummond ⎜Apr 25, 2019 ⎜ Company

In order to strengthen its position in the Asian market, isoSolutions has appointed a Sales and Marketing Manager for Asia. Mr. Eric Chang will be responsible for sales and marketing efforts in the Asian market. He will be supported by Mr. Hans Peng, Sales and Marketing Manager, China and Mr. Eric Huang, Sales and Marketing Representative, China (located in Shanghai). (more…)

Tags:

Preclinical efficacy of hK2 targeted [177Lu]hu11B6 for prostate cancer theranostics

Posted by David T. Drummond ⎜Apr 22, 2019 ⎜ Industry

Androgen ablating drugs increase life expectancy in men with metastatic prostate cancer, but resistance inevitably develops. In a majority of these recurrent tumors, the androgen axis is reactivated in the form of increased androgen receptor (AR) expression. Targeting proteins that are expressed as a down-stream effect of AR activity is a promising rationale for management of this disease. (more…)

Evaluation of 111In-DOTA-5D3, a Surrogate SPECT Imaging Agent for Radioimmunotherapy of Prostate-Specific Membrane Antigen

Posted by Kevin Yang ⎜Mar 25, 2019 ⎜ Industry

5D3 is a new high-affinity murine monoclonal antibody specific for prostate-specific membrane antigen (PSMA). PSMA is a target for the imaging and therapy of prostate cancer. 111In-labeled antibodies have been used as surrogates for 177Lu/90Y-labeled therapeutics. We characterized 111In-DOTA-5D3 by SPECT/CT imaging, tissue biodistribution studies, and dosimetry.
(more…)

Tags:

Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas

Posted by Kevin Yang ⎜Feb 25, 2019 ⎜ Industry

The role of concomitant peptide receptor radionuclide therapy (PRRT) and capecitabine therapy has shown benefit in gastroenteropancreatic neuroendocrine tumors. However, data reporting its role in paraganglioma (PGL) patients is lacking. The aim of this study was to evaluate the role of combined capecitabine and 177Lu-DOTATATE in malignant PGL patients. (more…)

Tags:

Therapeutic Radiometals: Worldwide Scientific Literature Trend Analysis (2008–2018)

Posted by David T. Drummond ⎜Feb 21, 2019 ⎜ Industry

Academic journals have published a large number of papers in the therapeutic nuclear medicine (NM) research field in the last 10 years. Despite this, a literature analysis has never before been made to point out the research interest in therapeutic radionuclides (RNs). For this reason, the present study aims specifically to analyze the research output on therapeutic radiometals from 2008 to 2018, with intent to quantify and identify global trends in scientific literature and emphasize the interdisciplinary nature of this research field. (more…)

Tags:

New strategic commercial Alliance between isoSolutions and Fenix Medica

Posted by David T. Drummond ⎜Feb 18, 2019 ⎜ Company

Vancouver and Buenos Aires, February 2019

We are very proud to announce a new strategic commercial Alliance between isoSolutions and Fenix Medica for the Latin American market. isoSolutions provides a one-stop shopping service as well as technical support worldwide for nuclear medicine products including: Radiochemicals, Stable isotopes, Labeled compounds, Sealed sources, Synthesizers, QC instruments, and Shielding products. (more…)

Tags:

Bone marrow cell homing to sites of acute tibial fracture: 89Zr-oxine cell labeling with positron emission tomographic imaging in a mouse model

Posted by Kevin Yang ⎜Feb 13, 2019 ⎜ Industry

Bone fracture healing is dependent upon the rapid migration and engraftment of bone marrow (BM) progenitor and stem cells to the site of injury. Stromal cell-derived factor-1 plays a crucial role in recruiting BM cells expressing its receptor CXCR4. Recently, a CXCR4 antagonist, plerixafor, has been used to mobilize BM cells into the blood in efforts to enhance cell migration to sites of injury presumably improving healing. (more…)

Tags:

Chinese Lunar New Year, Year of the Pig!

Posted by David T. Drummond ⎜Feb 5, 2019 ⎜ Company

Chinese Lunar New Year

isoSolutions wishes everyone health and prosperity in the Year of the Pig!

Tags:

ALASBIMN 2019 Annual Meeting

Posted by Marvin Calderon ⎜Jan 13, 2019 ⎜ Calendar

isoSolutions will be attending the ALASBIMN 2019 Annual Meeting to be held in Lima, Peru November 13 to 16, 2019. Marvin Calderon, Regional Sales and Marketing Manager Sales for Latin America hopes to see you there. If you would like to arrange a time and place to meet him, please contact mcalderon@isosolutions.com.

CANM 2019 Annual Meeting

Posted by Patricia Acton ⎜Jan 13, 2019 ⎜ Calendar

isoSolutions will be attending the CANM 2019 Annual Meeting to be held in Québec, QC, Canada February 07 to 09, 2019. Pat Acton, Regional Sales and Marketing Manager Sales for Canada and US hopes to see you there. If you would like to arrange a time and place to meet her, please contact pacton@isosolutions.com.

Reactors back online, expected to alleviate shortage of Mo-99

Posted by David T. Drummond ⎜Nov 20, 2018 ⎜ Industry

The worldwide supply of molybdenum-99 is expected to stabilize over the next several weeks as the High Flux Reactor in the Netherlands and the Open Pool Australian Lightwater nuclear reactor have resumed operations and are expected to reach normal Mo-99 production this week. Meanwhile, NTP Radioisotopes’ South Africa-based Pelindaba Nuclear Plant, which has finished functionality tests, is awaiting approval from the country’s National Nuclear Regulator to begin Mo-99 production runs.

Read the full article.

Tags:

Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors

Posted by Kevin Yang ⎜Nov 5, 2018 ⎜ Industry

Radiolabeled somatostatin analog therapy has become an established treatment method for patients with well to moderately differentiated unresectable or metastatic neuroendocrine tumors (NETs). The most frequently used somatostatin analogs in clinical practice are octreotide and octreotate. (more…)

Tags:

B.C. Cancer Foundation receives anonymous $18 million donation

Posted by David T. Drummond ⎜Oct 29, 2018 ⎜ Industry

A generous donor has given the B.C. Cancer Foundation $18.346 million, but insists on remaining anonymous.

“Today marks an important moment in cancer research and care in Canada with one of the largest donations ever made to bring new treatment solutions to patients,” said Sarah Roth, president and CEO of the B.C. Cancer Foundation. (more…)

Tags:

Monosodium glutamate reduces 68Ga-PSMA-11 uptake in salivary glands and kidneys in preclinical prostate cancer model

Posted by Kevin Yang ⎜Sep 21, 2018 ⎜ Industry

INTRODUCTION: Prostate-specific membrane antigen (PSMA) is an excellent prostate cancer target for theranostic applications. Many imaging agents showing high sensitivity/specificity for PSMA-expressing tissues have been developed. Some have been labeled with therapeutic radionuclides (i.e. 177Lu, 225Ac) and have had success in treating castration-resistant metastatic prostate cancer. The activity administered to patients is limited by toxicity to normal organs;

(more…)

Tags:

First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer

Posted by Kevin Yang ⎜Sep 12, 2018 ⎜ Industry

This first-in-human study demonstrated that 177Lu-EB-PSMA-617 had higher accumulation in mCRPC and that low imaging dose appears to be effective in treating tumors with high 68Ga-PSMA-617 uptakes. Elevated uptakes of 177Lu-EBPSMA-617 in kidneys and red bone marrow were well tolerated at the administered low dose. Further investigations with increased dose and frequency of administration are warranted. (more…)

Tags:

Single Low-Dose Injection of Evans Blue Modified PSMA-617 Radioligand Therapy Eliminates Prostate-Specific Membrane Antigen Positive Tumors

Posted by Kevin Yang ⎜Sep 6, 2018 ⎜ Industry

Prostate cancer is the most frequently diagnosed malignant tumor in men worldwide. Prostate-specific membrane antigen (PSMA) is a surface molecule specifically expressed by prostate tumors and has been shown to be a valid target for internal radionuclide therapy in both preclinical and clinical settings. The most common radiotherapeutic agent is the small molecule 177Lu-PSMA-617, (more…)

Tags:

United Pharmacy Partners (UPPI, LLC) 2018 Annual Meeting

Posted by Patricia Acton ⎜Sep 5, 2018 ⎜ Calendar

isoSolutions will be attending the United Pharmacy Partners (UPPI, LLC) 2018 Annual Meeting to be held in San Antonio, TX September 12 to 15, 2018. (more…)

Tags:

2018 Chinese Society of Nuclear Medicine Annual Meeting

Posted by Hans Peng ⎜Aug 2, 2018 ⎜ Industry

Since China was the highlighted country of 2018 SNMMI in Philadelphia, several CSNM board members presented a brief report of 2018 SNMMI to the audience. One interesting fact needs attention is that Lu-177 is the most discussed topic this year not only because Lu-177 is highly in demand during SNMMI, but also more and more professors and doctors in China have realized how important and effective Lu-177 is when it is used to diagnose and treat prostate cancer. (more…)

Tags:

Y-90 Radioembolization Long-Term Outcomes in a 185-Patient Cohort

Posted by Kevin Yang ⎜Jul 26, 2018 ⎜ Industry

Y-90 radioembolization for HCC patients with PVT appears to have an acceptable safety profile, with better survival in CP-A patients than in CP-B patients. This study confirms prior reports of survival in PVT patients treated with Y-90 radioembolization, and survival after Y-90 radioembolization appears to exceed that in
similar patients treated with systemic therapies. Despite the negative studies recently reported, Y-90 radioembolization is a reasonable treatment option in properly selected PVT patients. Further controlled studies are needed to compare it with systemic therapies or other locoregional treatments for advanced-stage HCC.

Nadine Abouchaleh1, Ahmed Gabr1, Rehan Ali1, Ali Al Asadi1, Ronald A. Mora1, Joseph Ralph Kallini1, Samdeep Mouli1, Ahsun Riaz1, Robert J Lewandowski1, and Riad Salem1–3

Info on purchasing Y-90, please contact sales@isosolutions.com

Read the full article PDF

Tags:

Chinese Society of Nuclear Medicine Annual Meeting 2018

Posted by Hans Peng ⎜Jul 11, 2018 ⎜ Calendar

The Chinese Society of Nuclear Medicine Annual Meeting will be held in Chengdu, Sichuan from 2018–07–12 to 2018–07–15. We hope to see you there and we can arrange a time and place to meet if you wish.

Tags:

19th China Cardiovascular and Nuclear Medicine Annual meeting

Posted by Hans Peng ⎜Jul 11, 2018 ⎜ Industry

isoSolutions Marketing and Management will send its representative in China, Eric Huang to the 19th China Cardiovascular and Nuclear Medicine Annual meeting organized by Chinese Society of Nuclear Medicine (http://www.csnm.com.cn/) in Sichuan, China.

The 19th China Cardiovascular and Nuclear Medicine Annual Meeting will be held in Chengdu, Sichuan from July 12 to July 15, 2018. (more…)

Tags:

SNMMI Image of the Year: PSMA PET Imaging of Theranostic for Advanced Prostate Cancer

Posted by David T. Drummond ⎜Jun 29, 2018 ⎜ Industry

PHILADELPHIA (Embargoed until 6:30 p.m. EDT, Tuesday, June 26, 2018) – In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to radionuclide therapy targeting prostate specific membrane antigen (PSMA) with the radionuclide lutetium-177 (177Lu). (more…)

Tags:

Can nuclear medicine avoid another Mo-99 shortage?

Posted by David T. Drummond ⎜Jun 11, 2018 ⎜ Industry

By Wayne Forrest, AuntMinnie.com staff writer.

Major changes are taking place in the intricate network that supplies healthcare providers around the world with molybdenum-99 (Mo-99), a key radioisotope for nuclear medicine studies. The question is, can the nuclear medicine community avoid another devastating shutdown like the one that occurred in 2009? (more…)

Tags:

Targeted a-Therapy of Metastatic Castration-Resistant Prostate Cancer Analysis Suggests Efficacy Regarding Duration of Tumor Control

Posted by Kevin Yang ⎜Jun 6, 2018 ⎜ Industry

A positive response for surrogate parameters demonstrates remarkable antitumor activity for 225Ac-PSMA-617. Swimmer-plot analysis indicates a promising duration of tumor control, especially considering the unfavorable prognostic profile of the selected advanced-stage patients. Xerostomia was the main reason patients discontinued therapy or refused additional administrations and was in the same dimension as nonresponse; this finding indicates that further modifications of the treatment regimen with regard to side effects might be necessary to further enhance the therapeutic range.

Clemens Kratochwil1, Frank Bruchertseifer2, Hendrik Rathke1, Markus Hohenfellner3, Frederik L. Giesel1, Uwe Haberkorn*1,4, and Alfred Morgenstern*2

Info on purchasing Ac-225, please contact sales@isosolutions.com .

Read the full article PDF

Tags:

Scholarship Awarded 2018

Posted by David T. Drummond ⎜May 7, 2018 ⎜ Industry

The Armstrong-Lepeska Science Marketing Scholarship, sponsored by isoSolutions, has been awarded to two more students. This scholarship is granted to a student at Langara College in Vancouver.  To highlight the importance of marketing and sales of high-technology, scientifically-intensive products, the scholarship awards a student in a scientific discipline who completes a course in Marketing.

(more…)

Tags:

Long–Half-Life 89Zr-Labeled Radiotracers Can Guide Percutaneous Biopsy Within the PET/CT Suite Without Reinjection of Radiotracer

Posted by David T. Drummond ⎜Apr 25, 2018 ⎜ Industry

PET/CT-guided percutaneous biopsy can be safely and accurately performed within the PET/CT suite without reinjection of the 89Zr-labeled radiotracer after the initial injection for diagnostic imaging. 89Zr-labeled radiotracers targeting specific proteins may be useful for both detection and molecular profiling in high-risk patients presenting with widely disseminated disease. Studies such as this may add clinical justification for the use of molecular imaging in interventional oncology and for promoting future access to interventional PET imaging facilities. (more…)

Tags:

PET myocardial perfusion imaging more effective than SPECT scans in detecting coronary disease

Posted by David T. Drummond ⎜Apr 6, 2018 ⎜ Industry

Key findings of the study:

  • Using PET scans instead of SPECT scans resulted in increased rates of diagnosis of severe obstructive coronary artery disease from 70 percent to 79 percent.
  • PET scans were associated with a lower incidence of invasive catheterization without identification of severe coronary artery disease (43% vs 55%). (more…)

Tags:

First validation of myocardial flow reserve assessed by dynamic 99mTc-sestamibi CZT-SPECT camera

Posted by Kevin Yang ⎜Mar 20, 2018 ⎜ Industry

99mTc-sestamibi CZT-SPECT is technically feasible and can provide similar result to 15O-water PET for detecting impaired myocardial flow reserve and abnormal fractional flow reserve in patients with coronary artery disease. This study highlights the diagnostic value of using 99mTc -sestamibi for patients with coronary artery disease.

The WATERDAY study: Denis Agostini & Vincent (more…)

Tags:

Prospective of 68Ga Radionuclide Contribution to the Development of Imaging Agents for Infection and Inflammation

Posted by David T. Drummond ⎜Mar 14, 2018 ⎜ Industry

During the last decade, the utilization of 68Ga for the development of imaging agents has increased considerably with the leading position in the oncology. The imaging of infection and inflammation is lagging despite strong unmet medical needs. This review presents the potential routes for the development of 68Ga-based agents for the imaging and quantification of infection and inflammation in various diseases and connection of the diagnosis to the treatment for the individualized patient management. (more…)

Tags:

99mTc-maraciclatide SPECT for prostate cancer bone metastases

Posted by Kevin Yang ⎜Mar 12, 2018 ⎜ Industry

Osteoclast activity is an important factor in the pathogenesis of skeletal metastases and is a potential therapeutic target. This study aimed to determine if selective uptake of 99mTc-maraciclatide, a radiopharmaceutical targeting αvβ3 integrin, occurs in prostate cancer (PCa) bone metastases and to observe the changes following systemic therapy. (more…)

Tags:

Tumor-Killing Targeted Radiation PRRT Approved by U.S. FDA

Posted by David T. Drummond ⎜Feb 14, 2018 ⎜ Industry

The first Peptide Receptor Radionuclide Therapy (PRRT) has received FDA approval. Lutetium 177 DOTA-TATE (Lu 177), a type of PRRT, is now approved for the treatment of somatostatin-receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut tumors in adults.

FDA approval of PRRT using Lu-177 will allow more eligible U.S. patients to receive this “life extending” treatment. Lu-177 is manufactured by Advanced Accelerator Applications (AAA), a Novartis company. Prior to the FDA approval, PRRT with Lu-177 was only available in a limited number of American treatment centers as part of an expanded access program or through a clinical trial.

Click here to see full news release.

Tags:

isoSolutions supplier IRE is proud to announce a partnership with ASML

Posted by David T. Drummond ⎜Feb 1, 2018 ⎜ Products

IRE is proud to announce a partnership with ASML to further develop a new, non-fission production method for medical isotopes such as Mo-99/Tc-99m. This partnership has resulted in the start of the LightHouse Isotopes BV, an ambitious initiative for the development of a promising alternative production method for a sustainable long term supply of Mo-99.

Click here to see full post.

Tags: